Patent details

93276 Product Name: Elotuzumab

Basic Information

Publication number:
93276
Type:
SPC
SPC Type:
Medical
Basic Patent Number:
EP078407467
Legal Status:
Inactive
Application number:
93276
First applicant's nationality:
Procedural language:
French

Marketing Authorization

Marketing Authorization Number:
EU/1/16/1088
Marketing Authorization Type:
Marketing Authorization Date:
13/05/2016
Marketing Authorization Status:
Accepted
Marketing Authorization Country:

Dates

Filing date:
24/10/2016
First Marketing Authorization date:
13/05/2016
Grant date:
27/12/2016
Activation date:
Publication date:
27/12/2016
Lapsed date:
Expiration date:
Renunciation date:
Revocation date:
Annulment date:
Basic SPC Expiration:
13/05/2031
SPC Extension Expiration:
13/05/2031
Rejection date:
Withdrawal date:

Owner

From:
24/10/2016
 
 

Name:
ABBVIE BIOTHERAPEUTICS INC.
Address:
1500 SEAPORT BOULEVARD, REDWOOD CITY, CA 94063, United States (US)

Name:
DANA-FARBER CANCER INSTITUTE, INC.
Address:
450 BROOKLINE AVENUE, BOSTON, MA 02215, United States (US)

Agent

Name:
DENNEMEYER & ASSOCIATES S.A. PATENT DEPARTMENT
From:
24/10/2016
Address:
PO Box 1502, 1015, LUXEMBOURG, Luxembourg (LU)
To:

Inventor

1

Name:
TAI Yu-Tzu
Address:
United States (US)

2

Name:
ANDERSON Kenneth, C.
Address:
United States (US)

3

Name:
AFAR Daniel
Address:
United States (US)

Annual Fees

Annual Fee Due Date:
31/08/2027
Annual Fee Number:
21
Annual Fee Amount:
410 Euro
Expected Payer:
Last Annual Fee Payment Date:
Last Annual Fee Paid Number:
Payer:
Filing date Document type Number of pages